MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $62.42M (cash outflow) rose 188.7% year over year, ahead of the +80.3% change in trailing-twelve-month net income. Sequentially, it rose 68.3% from the prior quarter. Over 3 fiscal years it compounded at +49.3% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$105.1M (+20.8%) for the fiscal year ending Dec 2026, a slowdown from the +40.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$62.42M+68.3% QoQ
- Last fiscal yearDec 2025
- -$86.97M+40.5% YoY
- LTMSep 2026
- -$145.1M+80.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +188.7% | +91.0% | -97.8 pp |
| 1 year | +40.5% | +20.8% | -19.6 pp |
| 3-year CAGR | +49.3% | +10.8% | -38.5 pp |
| 5-year CAGR | -17.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (86.97M) USD
- Year-over-year change
- -40.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (86.97M) | -40.5% |
| FY2024 | 2024-12-31 | (61.92M) | -90.2% |
| FY2023 | 2023-12-31 | (32.56M) | -24.6% |
| FY2022 | 2022-12-31 | (26.14M) | — |
Net Income vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +80.3% is the 5th highest of 8, against a peer median of +126.6%.
- Over three fiscal years its annual growth of +49.3% compares with a peer median of +1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €890.37M EUR | +482.2% | -27.9% | 73.7% | |
| LTM Jun 2026 | $534.8M USD | +211.7% | +73.5% | — | |
| LTM Sep 2026 | $193.81M USD | +0.8% | +2.8% | 69.0% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $148.96M USD | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $145.1M USD | +80.3% | +49.3% | — |
| LTM Mar 2026 | $110M USD | +489.6% | — | — | |
| LTM Mar 2026 | $91.08M USD | +0.9% | +1.3% | 253002.8% | |
| LTM Mar 2026 | $44.95M USD | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $12.01M USD | +126.6% | — | 3.8% | |
| Peer median (excluding MBX) | — | +126.6% | +1.3% | 71.4% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 306K | 2.04M | 5.22M | 8.68M |
| Change in Working Capital | 1.29M | (735K) | 4.6M | 1.58M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 671K | 412K | 3.93M | (2.46M) |
| Other Working Capital | 619K | (1.15M) | 670K | 4.03M |
| Other Non-Cash Items | 1.36M | (880K) | (2.82M) | (3.48M) |
| Operating Cash Flow | (23.12M) | (31.98M) | (54.68M) | (79.95M) |
| Capital Expenditures | (441K) | (129K) | (874K) | (1.93M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.22M) | (63.8M) | (239.47M) | (358.15M) |
| Sales of Investments | 9.25M | 33M | 79.75M | 267.87M |
| Other Investing Activities | 0 | 0 | 0 | 8.5M |
| Investing Cash Flow | (11.41M) | (30.93M) | (160.6M) | (83.71M) |
| Debt Repayment | 10M | 0 | 0 | 0 |
| Common Stock Issued | 30K | 739K | 174.54M | 189.59M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (428K) | (30K) | (3.94M) | 0 |
| Financing Cash Flow | 46.06M | 69.22M | 234.1M | 189.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.53M | 6.31M | 18.83M | 25.94M |
| Free Cash Flow | (23.56M) | (32.11M) | (55.56M) | (81.88M) |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.